Scott Rocklage is a venture partner of 5AM Ventures in Boston. Myotonic dystrophy is a disease that Scott and his team is trying to find a cure for. Myotonic is the leading cause of muscular dystrophy.
5AM and other venture companies are putting 55 million into fighting the deadly disease. DM1 only grows worse, so therefore Scott and his team are trying real hard to find a cure for this sickness.
Entire families can be affected with this disease, and that’s why it’s not taken lightly. The fund is being use to fight the disease and other illness relating to it. The genetic disorder can stay in families for long period of time, so the study is very detailed. Learn more about Scott Rocklage: http://chemistry.mit.edu/scott-rocklage-phd-2-and-his-wife-patty-are-celebrated-their-major-gift and http://people.equilar.com/bio/scott-rocklage-cidara-therapeutics-/salary/913398#.WWaMA9PytTY
Scott Rocklage studied chemistry at the University of California Berkley. Richard R. Schrock laboratory is where he performs some of his studies. Scott became managing partners of 5AM Ventures in 2004.
Rocklage has over 3 decades of experience in the health care industry. He is the reason for the approval of many medications including cubicin. Scott was also the CEO of a pharmaceutical company as well.
Scott serves on the board for a lot of companies and he is very passionate about what he does. His studies are respected amongst his peers and he is constantly making major advancement in the fields.
Rocklage currently work in Boston with 5AM venture and they are always working to bring great products to the market. You can search for Scott on LinkedIn if you will like to assist him.